Novartis AG
BISPECIFIC ANTIBODIES THAT BIND CD 123 CD3
Last updated:
Abstract:
The present invention is directed to novel bispecific anti-CD 123.times.anti-CD3 antibodies.
Status:
Application
Type:
Utility
Filling date:
1 Jun 2018
Issue date:
11 Jun 2020